Pluristem Therapeutics Inc. (PSTI) EPS Estimated At $-0.09

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Logo
Investors sentiment decreased to 0.9 in 2018 Q3. Its down 0.85, from 1.75 in 2018Q2. It turned negative, as 4 investors sold Pluristem Therapeutics Inc. shares while 6 reduced holdings. 4 funds opened positions while 5 raised stakes. 2.50 million shares or 6.75% more from 2.34 million shares in 2018Q2 were reported.
Citadel Advsrs Limited Liability Corporation reported 27,578 shares stake. Riggs Asset Managment owns 1,543 shares or 0% of their US portfolio. Two Sigma Securities Ltd Liability invested 0% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Virtu Financial Lc, New York-based fund reported 174,174 shares. State Street stated it has 48,978 shares. Advisory Service Net Lc has 1,000 shares. Art Ltd stated it has 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Geode Capital Mgmt Ltd Limited Liability Company stated it has 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Hightower Advsrs reported 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Citigroup holds 1,040 shares. West Oak Capital Ltd reported 0% stake. 181,700 were reported by California Employees Retirement System. 11,457 were accumulated by Tower Rech Capital Ltd Liability Corp (Trc). Raymond James And Assocs accumulated 0% or 105,293 shares. Financial Bank Of America De invested in 0% or 190 shares.

Analysts expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to report $-0.09 EPS on February, 5.After having $-0.08 EPS previously, Pluristem Therapeutics Inc.’s analysts see 12.50 % EPS growth. The stock increased 1.87% or $0.02 during the last trading session, reaching $1.09. About 162,233 shares traded. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 33.76% since January 14, 2018 and is downtrending. It has underperformed by 33.76% the S&P500.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $126.22 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

More notable recent Pluristem Therapeutics Inc. (NASDAQ:PSTI) news were published by: Benzinga.com which released: “Pluristem Therapeutics (NASDAQ:PSTI), Rexahn Pharma (NYSE:RNN) Are Biotech Winners, B Riley FBR Says In Bullish Initiation – Benzinga” on July 31, 2018, also Seekingalpha.com with their article: “Pluristem: A RegenBio Darling Founders In The Wind. Here’s Why You Should Take Another Look – Seeking Alpha” published on June 07, 2018, Globenewswire.com published: “Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy for the Treatment of Graft Failure and Incomplete Recovery Following Hematopoietic Cell Transplantation – GlobeNewswire” on September 25, 2018. More interesting news about Pluristem Therapeutics Inc. (NASDAQ:PSTI) were released by: Globenewswire.com and their article: “FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study – GlobeNewswire” published on January 09, 2018 as well as Globenewswire.com‘s news article titled: “Pluristem Issues Letter to Shareholders Nasdaq:PSTI – GlobeNewswire” with publication date: February 07, 2018.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.